Variation in surfactant protein D (SP-D) is associated with lung function in tobacco smoke-induced chronic respiratory disease. We hypothesized that the same association exists in the general population and could be used to identify individuals sensitive to smoke-induced lung damage. The association between serum SP-D (sSP-D) and expiratory lung function was assessed in a cross-sectional design in a Danish twin population (n ϭ 1,512, 18 -72 yr old). The adjusted heritability estimates for expiratory lung function, associations between SP-D gene (SFTPD) single-nucleotide polymorphisms or haplotypes, and expiratory lung function were assessed using twin study methodology and mixed-effects models. Significant inverse associations were evident between sSP-D and the forced expiratory volume in 1 s and forced vital capacity in the presence of current tobacco smoking but not in nonsmokers. The two SFTPD single-nucleotide polymorphisms, rs1923536 and rs721917, and haplotypes, including these single-nucleotide polymorphisms or rs2243539, were inversely associated with expiratory lung function in interaction with smoking. In conclusion, SP-D is phenotypically and genetically associated with lung function measures in interaction with tobacco smoking. The obtained data suggest sSP-D as a candidate biomarker in risk assessments for subclinical tobacco smoke-induced lung damage. The data and derived conclusion warrant confirmation in a longitudinal population following chronic obstructive pulmonary disease initiation and development. surfactant protein D; tobacco smoking; single-nucleotide polymorphisms; lung injury; forced expiratory volume in one second SURFACTANT PROTEIN D (SP-D) levels in bronchoalveolar lavage fluid (BALF) and serum SP-D (sSP-D) are suggested biomarkers for pulmonary injury in a variety of respiratory diseases, and sSP-D is associated with mortality (23, 30, 33) . The chronic lung inflammation, such as appears after long-term tobacco smoking, is assumed to alter the permeability of the lung-blood barrier (17), thereby allowing the passage of SP-D from the pulmonary compartment to the circulation. Tobacco smoking has been shown to be associated with decreased SP-D levels in BALF as well as with increased levels of sSP-D, indicating protein leakage to the circulation from inflamed lungs (22, 29, 32) .
lung-blood barrier (17) , thereby allowing the passage of SP-D from the pulmonary compartment to the circulation. Tobacco smoking has been shown to be associated with decreased SP-D levels in BALF as well as with increased levels of sSP-D, indicating protein leakage to the circulation from inflamed lungs (22, 29, 32) .
A decrease in sSP-D after steroid treatment was found in the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) multi-center study, which investigated patients with chronic obstructive pulmonary disease (COPD), and sSP-D was correlated with symptom relief (9) . Similar findings were obtained in a randomized placebo-controlled study, in addition to alterations in the forced expiratory volume in 1 s in percentage of that predicted (FEV 1 %pred) (28) . In additional studies of advanced patients, sSP-D was associated to exacerbations (21) and loss of lung density (5) . However, few studies have evaluated sSP-D associations in individuals with subclinical phenotypes and "at risk" individuals and the role of tobacco smoking.
Several single-nucleotide polymorphisms (SNPs) in the SP-D gene (SFTPD; 10q22.2-q23.1) are associated with sSP-D (9, 29) . Three SFTPD SNPs (including rs721917, a Met11Thr variation) were further associated with FEV 1 %pred in stable COPD (9) , whereas five SNPs were associated with increased risk of COPD development in a genome-wide association study (18) . Moreover, rs721917 is reported to have a significant association with both lung cancer and with emphysema (13) (14) (15) .
Tobacco smoking is considered to be the major environmental risk factor for lung function decline and COPD. Nevertheless, tobacco smoking only accounts for ϳ15% of the variation in lung function (4) , and the subgroup of smokers who are susceptible to developing persistent airway inflammation remains unclearly characterized.
In the present study, we sought to test the hypotheses that sSP-D could serve as a proxy for smoke-induced preclinical pulmonary damage associated with lung function measures and that SFTPD variants contribute to the genetic variation in lung function in the general population. We used twin methodology and a mixed-effects model framework to determine these associations. Our data support that sSP-D may serve as biomarker in smokers and not in nonsmokers.
MATERIALS AND METHODS
Ethical considerations. Written informed consent was obtained from all twins, and the study was conducted according to the Helsinki declaration. The study was approved the Regional Scientific Ethical Committee for Southern Denmark, who briefed other regional and national committees because of the nationwide nature of the study.
Study population. The study population included participants in GEMINAKAR, a nationwide Danish twin study previously described in detail (3, 27) . A total of 756 twin pairs, 309 monozygotic, 316 same-sex dizygotic, and 131 opposite-sex dizygotic twins, underwent full-day examinations from 1997 to 2000.
Lung function testing, blood sample collection, and sSP-D analysis. Forced spirometry was conducted by trained study nurses on both twins on the same day at two different investigational centers, according to the most recent guidelines at that time (2) . Spirometry was performed using a Vitalograph dry-bellow spirometer in Copenhagen and a noncommercial pneumotachograph in Odense. Prior or present medical history of respiratory disease, registration of current medications, information regarding tobacco smoking status, and prior tobacco smoking history were obtained by questionnaire. Blood samples were drawn the same day and stored at Ϫ80°C until analysis. sSP-D was measured using a sandwich ELISA, as previously described (20) .
Genotyping. Seven SNPs, rs1923534, rs1923536, rs12770776, rs721917, rs17878336, rs2243639, and rs3088308, were selected for genotyping, which was performed on 1,440 subjects using TaqMan genotyping assays following the manufacturer's recommendations (Applied Biosystems, Foster City, CA) ( Table 1) . A schematic view of the positions and linkage disequilibrium (LD) plot is depicted in Fig. 1 . The strongest linkage disequilibrium within SFTPD (Fig. 2) . When comparisons of continuous variables between the groups were made, t-test variances were used for two-group comparisons, and a one-way ANOVA with Bonferroni post hoc analysis was used for three-group comparisons. The significant effects associated with outcome variables were estimated using classical twin methodological variants of mixed-effects regression models, which also provides estimates of heritability, fitted using the statistical tool (twinlm) in the Analysis of Multivariate Events mets-package in R (ver.2.15) (11) . The most parsimonious models were chosen according to Akaike's Information Criterion (AIC) (1), aiming at minimizing AIC. Graphs illustrating associations between sSP-D and FEV1 were created in predxcon, after adjustment for covariates.
Analysis of genotype-phenotype association. SNPs were tested for Hardy-Weinberg equilibrium using genhw command, based on chi 2 test, in STATA (ver. 11). Linkage disequilibrium (LD) was evaluated in Haploview (ver. 4.2). An analysis of the association between SNPs and quantitative traits was performed using the most parsimonious twin model from heritability analyses, as described above. The interactions between SNPs and current tobacco smoking were further tested.
The haplotypes were inferred using the 2SNP package with the linear mixed-effects model implemented in the lmekin function in the free R package kinship (31) . With this model, we were able to explicitly model the genetic relationship in monozygotic and dizygotic twin pairs to assess haplotype associations. The haplotypes were analyzed by a three-SNP sliding-window approach and by assuming an additive effect. The regression model allows for the estimation of the main effects and the interaction effects between haplotypes and covariates. 
Assays were produced by Custom TaqMan Single-Nucleotide Polymorphism (SNP) Genotyping Assay Service, except for assay HSPD32-YCMT, which was produced by Assays-by-Design (SM) Service. SNP Genotyping. f, forward primer; r, reverse primer.
RESULTS
Association between sSP-D levels and expiratory lung function measures. sSP-D was measured in 1,476 of a total of 1,512 subjects; 20 subjects were excluded due to recent or ongoing airway infection, which could potentially affect sSP-D and forced expiratory lung function measures. Of these subjects, 1,355 had technically satisfactory measurements based on forced spirometry. Fifty-seven subjects (4%) had self-reported respiratory disease (asthma ϭ 55, emphysema ϭ 1, sarcoidosis ϭ 1). There was no significant difference in sSP-D in these diseased subjects (1,142 Ϯ 635 ng/ml) relative to the residual subjects in the cohort (1,111 Ϯ 637 ng/ml) (P ϭ 0.7).
The basic characteristics of all subjects, stratified by tobacco smoking, are presented in Table 2 . The sSP-D levels were significantly higher in current tobacco smokers than in neversmokers (P Ͻ 0.0001) and ex-smokers (P Ͻ 0.0001), whereas the difference between the never-smokers and ex-smokers was not significant (P ϭ 0.06).
No main effects in expiratory lung function were observed by mixed-effects model with sSP-D as a response variable. However, there was a significant negative association between sSP-D and tobacco smoking and the interaction effects "current tobacco smoking*FEV1" (P ϭ 0.0003), "current tobacco smoking*FVC" (P ϭ 0.007), and "current tobacco smoking* FEV1/FVC" (P ϭ 0.003). These associations remained significant after correction for "respiratory disease" (Table 3) . Thus sSP-D was inversely correlated with expiratory lung function measures but only in smokers and not in nonsmokers. The relative largest effect was that a 1-l decrease in FEV 1 was associated with a sSP-D increase of 141 ng/ml in smokers. The relationships between sSP-D and FEV1, stratified by tobaccosmoking status, are illustrated in Fig. 1 .
Heritability of lung function. Data from intact twin pairs, with both twins having reliable forced spirometry measurements and neither twin affected by respiratory disease (chronic or acute), were used for a heritability analysis. These subjects included 269 monozygotic pairs, 266 same-sex dizygotic pairs, and 106 opposite-sex dizygotic pairs. The best fitting model was the additive genetic influences (A) and unique environ- Table 4 ). The AE model decomposes the variances into and suggests the variation in expiratory lung function predominantly to be caused by additive genetic effects.
SFTPD SNP associations with sSP-D and lung function measures.
The frequencies of SNPs in the total number of genotyped twin subjects (1,440) are presented in Table 5 . All SNPs were in Hardy-Weinberg disequilibrium, with the exception of one SNP, rs2243639, which was close to Hardy-Weinberg disequilibrium (estimated disequilibrium coefficient ϭ 0.01, P ϭ 0.09).
The genetic association analysis using sSP-D as a response variable revealed significant negative dosage effects of the minor alleles of rs1923534, rs12770776, rs721917, and rs3088308. There were positive dosage effects of rs17878336 and 1923536 (Table 6, Fig. 3, A-F) . The figures show that effects were similar in nonsmokers and smokers. In line with this, interactions between SNPs and current smoking were not significant, and an interaction effect was not included in the statistical analyses of relations between SNPs and sSP-D as shown in Table 6 .
Analyses of the associations between SFTPD SNPs and FEV 1 (Table 6 ) revealed significant negative associations between rs1923536 and rs721917 in interaction with current tobacco smoking and negative association with rs2243639 independently from smoking, whereas the association was positive for rs1923534 (Fig. 4, A-D) . Moreover, a negative association was found between FVC and rs1923536 in interaction with current tobacco smoking ( Table 6 ). The associations found for rs1923536 remained significant after correction for multiple testings (Table 6 ). In short, these complex patterns of associations showed that two SNPs located in the 5=-region (rs1923534 and rs1923536) appeared to influence sSP-D and expiratory lung function in inverse directions in smokers. In contrast, the traditionally investigated coding SNP rs721917 (Met11Thr) appeared to influence sSP-D and expiratory lung function in parallel directions in smokers.
Haplotype association between sSP-D and lung function measures. Several haplotypes constructed from the three-SNP sliding window analysis were associated with the sSP-D level ( Table 7 ). The direction of effects inferred from the SNP association with sSP-D was repeated in the direction of the effects from the haplotype analyses. The highest level of significance for haplotype associations with sSP-D was found for haplotypes including rs721917. The most significant haplotype included the major alleles of rs1923536 and rs12770776 and minor allele of rs721917 (P ϭ 6.6e-27).
Several significant associations were found between SFTPD haplotypes and FEV 1 or FVC in interaction with smoking. The highest degrees of significance were found for the associations between FEV 1 or FVC, with the haplotype including the major allele of rs17878336 and minor alleles of rs721917 and rs2243639 (P ϭ 0.003 and P ϭ 0.0007, respectively). This haplotype (frequency ϭ 29%), which contained two structural variant SNPs, inferred decreased sSP-D and also appeared to decrease expiratory lung function in smokers.
DISCUSSION
The present study showed a significant inverse relation between lung function and sSP-D in smokers. The results are in agreement with previous findings from diseased cohorts, whereby sSP-D was suggested to reflect smoke-induced inflammation in the lungs (21, 32) . However, our observations are obtained from a general population. Moreover, the present findings indicate that genetic SP-D variations may influence lung function in smokers in the general population.
There is some controversy regarding the association between sSP-D levels and expiratory lung function in disease. Olesen et al. In the present study, we found a negative association between sSP-D and expiratory lung function in smokers. The relatively largest effect was that a 1-l decrease in FEV 1 was associated with a sSP-D increase of 141 ng/ml in smokers. There was, however, no evident association in ex-smokers. Because most COPD cohorts comprise both smokers and ex-smokers/nonsmokers, this observation may putatively explain the lack of correlation in previous studies. Our observations support the general notion that sSP-D reflects inflammatory lung damage but further suggest that it is acute tobacco smoke-induced sSP-D that can serve as a significant lung damage biomarker in the adult population without infection or other severe pulmonary disease.
SNP and haplotype analyses have previously shown associations between SFTPD genotypes and COPD and associations with the quantitative traits FEV 1 and FVC. In particular, rs721917 (Met11Thr), a variation in the NH 2 -terminal domain of the SP-D molecule, is suggested to play a role in pulmonary disease development and has been shown to influence oligomerization, immunological function, and serum levels of the molecule (9, 14, 15, 20) . Consistent with previous studies, we observed a negative association between sSP-D and the minor allele of rs721917 (10) . We also found a negative association between the minor allele of rs721917 and lung function in the smokers in this general population. However, we found a stronger negative association with lung function for rs1923536, an SNP located in the 5=-gene regulatory sequence; the presence of the minor allele of this SNP was associated with a 264-ml decrease in FVC in smokers. The statistical strength of the association between SNPs and expiratory lung function measures appeared weak but was comparable to the strength of the association with COPD phenotypes in a previous study of SFTPD variation (9) .
Using SFTPD haplotype analysis, our findings paralleled those of the SNP analysis with regard to associations with sSP-D, and the observations represent a further extension of the previously well-described high degree of genetic determination of sSP-D (29) . The highest level of significance for a SFTPD haplotype association with lung function was found for one haplotype, including the minor alleles of rs721917 and one additional structural polymorphism, rs2243639. This haplotype had a frequency of 29% and was associated with a 100-ml decrease in FVC in smokers.
Based on the relation between smoke-induced increases in sSP-D and lowered lung function, it could be expected that SNPs increasing sSP-D would infer decreases in lung function and vice versa. However, cigarette smoke and pulmonary disease will increase systemic SP-D irrespective of the SFTPD genotype, although to different degrees according to the genotype.
However, both inverse and parallel relations between SNP/ sSP-D and SNP/lung function were found in this study. The parallel associations seen for the coding SNP rs721917 are partly in line with observations from Ishii et al. (15) , who used two small Japanese populations to demonstrate that subjects with a minor allele at rs721917 are more susceptible to emphysema investigated by high-resolution computed tomogra- N, numbers; F, frequency; MAF, minor allele frequency; Met, methionine; Thr, threonine; Leu, leucine; Val, valine; Ala, alanine; Ser, serine. phy. A resembling relation was found in the NETT-NAS study, where this minor allele of rs721917 was overrepresented in COPD (9) . The paradoxical pattern of association may imply that it is genetically determined structural SP-D variation, which affects the lung function rather than the genetically determined level of sSP-D synthesis. Alternatively, the investigated SNPs may be linked to other genetic variation within or outside SFTPD that determine expiratory lung function. The level of significance for our haplotype analyses was higher than the level of significance obtained using single-SNP analyses. However, it was beyond the scope of the study to determine whether the investigated SNPs were functional or markers of other functional SNPs in neighboring genetic regions.
A fraction (4%) of the twins had self-reported respiratory disease and thus cannot be classified with subclinical lung damage. Estimations of the association between sSP-D and expiratory lung function provided in Table 3 are, however, corrected for the presence of respiratory disease by inclusion of this covariate in the statistical analysis. Self-reported respiratory disease affected neither the association between SFTPD variation and sSP-D nor between SFTPD variation and expiratory lung function. As a sensitivity analysis, when those subjects with self-reported lung disease were excluded, we obtained similar results.
Due to the nature of the study, we were able to determine the heritability of lung function. We have previously determined sSP-D heritability as h 2 ϭ 0.83 (29) . We also found high heritability estimates, 0.79 for FEV 1 and 0.80 for FVC, in the present investigation. Other twin studies have shown varying adjusted heritability estimates of FEV 1 and FVC in adults, ranging from 0.3 to 0.9 (12, 25) . In accordance with a previous Danish twin study (13) , we found that the best explanatory model for FEV 1 variation included additive genetic effects and individual environmental effects.
The strength of this study was the large number of investigated subjects, allowing for the analysis of subgroups within the study population. We were also able to investigate the variation in lung function in individuals without evident disease. Most pulmonary biomarker studies to date have examined cohorts with advanced respiratory diseases, with the biomarkers likely reflecting events within the established disease, such as exacerbations or comorbidities, rather than the propensity for disease development. There are also shortcomings of this study. Only tobacco smoking was available as a descriptor for environmental exposure, and the study was not designed to identify additional SNP variations within SFTPD, flanking regions, or neighboring genes, which may contribute to the observed genotype-trait associations. Moreover, due to the cross-sectional design, we were not able to elucidate whether the associations between sSP-D and lung function can predict future clinical disease states.
The most important limitation in relying on lung function only in COPD prognosis is that lung function is a remarkably poor predictor of disease activity; it is impossible to know from measures of lung function whether the underlying inflammation is aggressive or still ongoing. Our data show that both sSP-D and expiratory lung function measures are reversible to a normal state in ex-smokers, supporting the notion that sSP-D may serve as biomarker in smokers and not in ex-smokers. Other studies have demonstrated that sSP-D is increased in advanced smoke-induced disease with association to exacerbations (21) but also significantly associated with baseline lung density and its decline over time (5) . On that basis, we suggest that sSP-D likewise may reflect inflammatory events essential in COPD initiation.
Surrogate markers capable of reflecting early changes in smoke-induced pathology may be beneficial for the early identification of individuals "at risk" of developing COPD (19) , and sSP-D has the potential to serve as an indicator of Only haplotypes with a frequency (Freq.) Ͼ4%, are shown and analyzed for associations to the quantitative traits serum Surfactant Protein D (sSP-D), forced expiratory volume in 1 s (FEV1), and/or forced vital capacity (FVC). 0: major allele, 1: minor allele. Interaction effects were calculated for haplotypes and current tobacco smoking. Covariates: sex, age, weight, height, tobacco smoking, haplotype-current tobacco smoking interaction. Main: Main effects, Interaction: interaction effects, ␤: ␤-coefficient resulting from analysis using nontransformed values (sSP-D: ng/ml, FEV1: mL, FVC: mL), p †: nominal P value obtained using nontransformed values, p ‡: nominal P value obtained using transformed values.
a P Ͻ 0.05, b P Ͻ 0.01, c P Ͻ 0.001, d P Ͻ 0.0001, e P Ͻ 0.00001.
COPD susceptibility in active tobacco-smoking individuals. Current guidelines recommend against the spirometric screening of asymptomatic individuals, regardless of COPD risk factors (26) . These recommendations are based on the lack of evidence for beneficial pharmacotherapy to treat asymptomatic persons with or without airflow obstruction; thus, screening for "persons at risk" using surrogate markers could be a futile effort. However, recent reports have indicated that pharmacotherapies can improve symptoms, exacerbation frequency, rate of FEV 1 decline, and mortality in individuals with mild and moderate COPD (6, 7, 16) . On this basis, the identification of persons at risk may enable early intervention with pharmacological treatment in addition to the recommendation of tobaccosmoking cessation. In summary, the present findings suggest that sSP-D can serve as a biomarker for subclinical inflammatory lung damage in smokers in the general population. We further found that genetic variations in SFTPD were associated with lower lung function in interaction with smoking and thereby may affect obstructive disease development. Longitudinal studies are warranted to validate whether sSP-D measurements provide information complementary to spirometric measures in the identification of persons at high risk of developing smoking-induced COPD.
